Chapter 8: Screening for cervical cancer in developing countries.
about
Effectiveness of VIA, Pap, and HPV DNA testing in a cervical cancer screening program in a peri-urban community in Andhra Pradesh, IndiaCervical cancer screening in developing countries at a crossroad: Emerging technologies and policy choicesDeveloping the Evidence Base to Inform Best Practice: A Scoping Study of Breast and Cervical Cancer Reviews in Low- and Middle-Income CountriesCancer Screening: Should Cancer Screening be Essential Component of Primary Health Care in Developing Countries?Advancing cervical cancer prevention in India: implementation science prioritiesImplementation science in cancer prevention and control: a framework for research and programs in low- and middle-income countriesCervical cancer prevention and treatment research in Africa: a systematic review from a public health perspectiveKnowledge, attitude and practice about cancer of the uterine cervix among women living in Kinshasa, the Democratic Republic of CongoEpidemiology and prevention of human papillomavirus and cervical cancer in sub-Saharan Africa: a comprehensive review.Effectiveness of a simple rapid human papillomavirus DNA test in rural NigeriaAn exploration of opportunities and challenges facing cervical cancer managers in Kenya.Program spending to increase adherence: South African cervical cancer screeningPrevalence of HPV infection and other risk factors in a Fijian population.See-and-treat approaches to cervical cancer prevention for HIV-infected women.Cervical cancer and HPV vaccination: Knowledge and attitudes of adult women in Lusaka, ZambiaDeterminants of VIA (Visual Inspection of the Cervix After Acetic Acid Application) positivity in cervical cancer screening of women in a peri-urban area in Andhra Pradesh, India.The levels of anti-HPV16/18 and anti-HPV31/33/35/45/52/58 antibodies among AS04-adjuvanted HPV16/18 vaccinated and non-vaccinated Ugandan girls aged 10-16 yearsHuman papillomavirus (HPV) testing on self-collected specimens: perceptions among HIV positive women attending rural and urban clinics in South AfricaMultimodal nonlinear optical microscopic imaging provides new insights into acetowhitening mechanisms in live mammalian cells without labeling.Cervical cancer risk factors among HIV-infected Nigerian womenThe prevalence of precancerous cervical cancer lesion among HIV-infected women in southern Ethiopia: a cross-sectional studyAspects of prophylactic vaccination against cervical cancer and other human papillomavirus-related cancers in developing countries.Cost evaluation of reproductive and primary health care mobile service delivery for women in two rural districts in South Africa.High-risk human papillomavirus in HIV-infected women undergoing cervical cancer screening in Lilongwe, Malawi: a pilot study.Epidemiology of cervical cancer with special focus on India.The age-specific prevalence of human papillomavirus and risk of cytologic abnormalities in rural Nigeria: implications for screen-and-treat strategiesInfluence of Spirituality and Modesty on Acceptance of Self-Sampling for Cervical Cancer Screening.Health and economic impact of HPV 16/18 vaccination and cervical cancer screening in Eastern Africa.Barriers to utilisation of cervical cancer screening in Sub Sahara Africa: a systematic review.Recurrence of cervical intraepithelial lesions after thermo-coagulation in HIV-positive and HIV-negative Nigerian women.Expanding Cervical Cancer Screening and Treatment in Tanzania: Stakeholders' Perceptions of Structural Influences on Scale-Up.Knowledge about Cervical Cancer and Associated Factors among 15-49 Year Old Women in Dessie Town, Northeast Ethiopia.Costs of cervical cancer screening and treatment using visual inspection with acetic acid (VIA) and cryotherapy in Ghana: the importance of scale.Determinants of Cervical Cancer Screening Accuracy for Visual Inspection with Acetic Acid (VIA) and Lugol's Iodine (VILI) Performed by Nurse and Physician[Safety of human papillomavirus 6, 11, 16 and 18 (recombinant): systematic review and meta-analysis].Accuracy of combinations of visual inspection using acetic acid or lugol iodine to detect cervical precancer: a meta-analysis.A fully integrated paperfluidic molecular diagnostic chip for the extraction, amplification, and detection of nucleic acids from clinical samples.HPV and cervical cancer: screening or vaccination?Safety and immunogenicity of human papillomavirus-16/18 AS04-adjuvanted vaccine: a randomized trial in 10-25-year-old HIV-Seronegative African girls and young womenA novel vaccine for cervical cancer: quadrivalent human papillomavirus (types 6, 11, 16 and 18) recombinant vaccine (Gardasil).
P2860
Q21136074-044E4A95-2FC1-4456-B035-C67D2A80F8EAQ26775085-62F50191-0E5E-40F8-9B54-5C86119B549CQ26795628-AB1AFE25-3079-475D-A548-33CD8A5884BCQ26799937-6BE3F546-AAF3-4A06-8EAC-B6191EDDBE57Q26824471-87900124-2729-478D-BA85-9FCBED79B99AQ27013654-3C415C9C-9646-4CAE-A38C-3A689DBF8148Q28601706-D5DB2F88-6788-40EE-A755-172F19A6877CQ28658479-71D96F2F-8A75-4142-B4B2-1668464422F2Q30227546-9998193A-5093-4BA5-88A9-828F498FE70BQ30415760-AD9F2FA1-91A8-4826-9F32-2ECA6C73F4F5Q30538864-6C2CAF66-03A8-44F2-BE67-D25DF166BD85Q33459276-93D88C1C-AEC0-4A9B-884A-5BF47F4551ABQ33694151-C2B9178C-CFE6-45A4-BFB7-A26C10D19236Q33754163-56243677-A02E-41B2-83F7-9BFF87AF5D97Q33819370-195BC1B3-13E1-4729-A2DB-C269847F22BAQ34033824-66261888-3575-4942-A7B0-90573BA0C1A6Q34152234-F5927E1A-E330-4A2A-BA87-070AE8FF6C5DQ34496820-AA182C22-C285-4D25-9AE4-9BE4D94AF137Q34505427-0D314912-D8AD-4822-A929-4A2305F756B5Q34773250-289C561E-2DFB-4E2A-A2D8-99BFE8AE1B1FQ35078412-51129653-5121-4237-9249-9466F9F0E06DQ35117498-E8141A79-A4ED-4783-8758-B0367825130DQ35159171-48E1E693-8B16-4626-93E7-5C04B4A5B958Q35186321-66345D60-7EBF-4484-97A5-AD079AB0B136Q35508006-06B48BFA-BBEB-40F7-8604-6C82A298FE1CQ35583144-F655C30A-B5E1-47BE-AA60-C0C2BB1D9A5AQ35830446-D9A7DF68-8018-445E-B492-FBAB84323E9AQ35858737-8F1C9279-1D69-4418-80EB-0A6A89E2D86CQ35916878-CFC3848A-BC5E-44CB-9283-F71FA756F493Q36015006-3DAC6D41-82D2-4B8B-AAB3-96BE7C1AC672Q36064814-9D65779E-C026-4D58-AAFA-F042BC76A924Q36149942-1736C4D9-4666-4256-91D4-903C8E5E8C7EQ36195826-32CA94DE-0E7A-4CF5-8F2E-996A2E942D20Q36255806-CD95D35F-96E0-4254-800E-1B0BD23AAAA5Q36388694-22F5278B-D430-40BE-BF15-64C740C5E329Q36398896-EEAC1B1F-FF23-4B02-9D34-786CBF40F923Q36563683-6AD14C00-3777-43C6-A4FD-0BB7B7914D4CQ36608826-401F5813-8A29-45F1-9C64-8241DC112997Q36796538-B8AB0D0B-6ABD-4628-B938-2F55541A6F4BQ36822935-0DF15E10-2AA9-4F98-9B1B-A6DB8F9406E6
P2860
Chapter 8: Screening for cervical cancer in developing countries.
description
2006 nî lūn-bûn
@nan
2006年の論文
@ja
2006年論文
@yue
2006年論文
@zh-hant
2006年論文
@zh-hk
2006年論文
@zh-mo
2006年論文
@zh-tw
2006年论文
@wuu
2006年论文
@zh
2006年论文
@zh-cn
name
Chapter 8: Screening for cervical cancer in developing countries.
@ast
Chapter 8: Screening for cervical cancer in developing countries.
@en
type
label
Chapter 8: Screening for cervical cancer in developing countries.
@ast
Chapter 8: Screening for cervical cancer in developing countries.
@en
prefLabel
Chapter 8: Screening for cervical cancer in developing countries.
@ast
Chapter 8: Screening for cervical cancer in developing countries.
@en
P1433
P1476
Chapter 8: Screening for cervical cancer in developing countries
@en
P2093
Lynette Denny
R Sankaranarayanan
P304
P356
10.1016/J.VACCINE.2006.05.121
P407
P478
24 Suppl 3
P577
2006-08-01T00:00:00Z